Raymond James analyst John Ransom set AmSurg’s price target at $60 and upgraded his recommendation to “buy,” according to a Value Walk report.
The upgrade was made closely following AmSurg’s announcement of intention to acquire Sheridan Healthcare for $2.35 billion.
More Articles on Transactions and Valuation Issues:
4 Recent ASC Industry Acquisitions
Beloit Health System ASC Project Remains in Limbo
3 Recently Opened & Expanded Ambulatory Surgery Centers
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.